诺华地拉罗司纳入医保了吗？

(Deferasirox) is an iron chelator product developed by Novartis Pharma Schweiz AG in Switzerland. It is a tridentate iron chelator that can form a complex with ferric ions in a ratio of 2:1 and is excreted from the feces, thereby reducing the iron content in the human body. The drug is also the first oral iron anthelmintic approved by the U.S. FDA for routine use, and is recommended in Europe as a first-line drug for thalassemia iron overload patients over 6 years old.

Novartis of Switzerland has always been focused on the growth area of pharmaceuticals and health care. It not only has innovative drugs, but also has a diversified business portfolio such as consumer health products to best meet the needs of patients and society. As one of Novartis’ innovative drugs, deferasirox has received widespread attention once it was launched. Based on the efficacy of this drug, patients can take it with confidence. So, is Novartis deferasirox included in medical insurance?

In November 2005, deferasirox was approved for marketing by the U.S. Food and Drug Administration (FDA); in 2010, the drug was approved for official marketing in China. At present, Novartis deferasirox has been included in the scope of medical insurance, and patients can rely on medical insurance to reimburse part of the cost when purchasing the drug. However, for many patients who require long-term treatment with deferasirox, the high cost of medication is still unaffordable. In order to reduce out-of-pocket expenses as much as possible and reduce the financial burden on patients themselves, patients can purchase drugs overseas through Medical Companion Travel and choose drugs with higher cost performance.

According to Medical Companion Travel, Novartis deferasirox is very cheap abroad, with a price of about $400 for a 400mg*30 tablet/box. However, the price of Novartis deferasirox, produced by Cipla in India, is only 1/2 of the price of the original drug. Patients in need can contact Medical Companion Travel to obtain their drug purchase channels.

Recommended hot articles: /newsDetail/92189.html